AVAC and Partners at ICASA 2023

Join AVAC and partners for the biennial International Conference on AIDS and Sexually Transmitted Infections (ICASA), in Harare, Zimbabwe December 4-9. More than 30 of our partners will convene at the meeting to champion community leadership and amplify their role in shaping local, national and global responses and delivering impactful advocacy. Community leadership on a range of issues are instrumental to: 

  • Accelerate and expand access to proven prevention options that people want and need. 
  • Dismantle the structural barriers to health faced by key populations. 
  • Intensify demands for robust domestic and global funding for health. 
  • Integrate HIV services with sexual and reproductive health. 
  • And much more. 

Scroll down for a roadmap to ICASA’s prevention program, and details on sessions and events that you won’t want to miss. 

Sessions of Interest

Sunday, December 3

  • Biomedical Prevention Forum 
    9:00-15:00 GMT 
    The Biomedical Prevention Forum will be held as a hybrid event bringing together advocates, civil society representatives, researchers, government officials and front-line providers to explore and discuss the latest advancements, challenges, and opportunities in biomedical HIV prevention, while emphasizing the importance of choice and its transformative impact on HIV prevention efforts. This is an open event. Register here. 
  • Key Populations Preconference 
    9:00-15:00 GMT 
    The Africa Key Populations Experts Group (AKPEG), African Sex Workers Alliance (ASWA), the African Network of People Using Drugs (AfricanPUD) and African Queer Youth Initiative (AQYI) Advocates for Prevention of HIV and AIDS in Africa (APHA), Global Black Gay Men Connect (GBGMC) and partners will host a safe platform to deliberate on the state of the HIV epidemic among Key Populations and to determine the stumbling blocks for progress on the path that ends AIDS for Key Populations.

Monday, December 4

Tuesday, December 5

  • Advancing Integrated Biomedical Prevention: Best Practices from Zimbabwe (Session 2) 
    8:45-09:30 GMT
    This satellite session will discuss best practices and lessons learned from the delivery of biomedical HIV prevention and Voluntary Medical Male Circumcision services as we work to further universal health coverage and robust health systems. Partners will launch a global call to action to unite, mobilize, and advocate for continued prioritized funding, sustained commitment, and strategic integration of VMMC into national and global prevention strategies.
  • Catalyzing a sustainable HIV prevention agenda: Approaches to expand local action on global commitments
    10:45-11:30 GMT
    Leveraging new strategic plans for HIV prevention, including the PEPFAR’s 5-year Strategy and UNAIDS’ Prevention Road Map, this satellite session will discuss combination prevention in the context of a sustainable HIV response and highlight a variety of approaches and models that leverage country and stakeholder-led innovations to meet the challenge.
  • Coordinating Implementation Science for CAB for PrEP: BioPIC’s Implementation Study Tracker 
    12:25-12:35 GMT
    In this oral abstract session, AVAC will present a new dashboard, which reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late-stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring.
  • Policy, Politics and HIV Management 
    13:05-13:50 GMT
    In this oral abstract session, Princess Mharire from Pangaea Zimbabwe AIDS Trust (PZAT) will present, Beyond Metrics: How the Simple Participatory Assessment of Real Change (SPARC) Tool Provides a Holistic Approach to Advocacy Measurement, and Joseph Njowa of PZAT will share the COMPASS MERL model in a presentation, Innovative tools for planning, monitoring, and evaluation of advocacy campaigns. 

Wednesday, December 7

Friday, December 8

  • Strengthen integration for better SRHR outcomes 
    10:45-11:30 GMT
    This concurrent session will feature Advocates for Prevention of HIV and AIDS in Africa’s (APHA) Yvette Raphael and will explore linkages between unintended pregnancies, unsafe abortion, and HIV.
  • HIV Prevention-Right Place, Right time 
    13:05-13:50 GMT
    This concurrent session will feature Maureen Luba of AVAC, Definate Nhamo of PZAT and Yvette Raphael of APHA. 

AVAC and Partner Poster Presentations

Tuesday, December 5 

  • Maximizing private pharmacies for PrEP delivery to increase uptake: Lessons learnt from the Community Retail Pharmacy Distribution Point, Ruth Akulu 

Wednesday, December 6 

  • Journalist Training: A Key Advocacy Strategy, Catherine Madebe
  • Perceptions on the new biomedical HIV prevention methods among adolescent girls and young women in tertiary institutions in Zimbabwe, Cleo Makura
  • Lessons from Crisis Response from TaNPUD in Enhancing Harm Reduction from 2015 to 2018, Marineus Mutongore
  • Implementing Community led Monitoring for improved quality of HIV services in Tanzania, Mathew Kawogo
  • Impact of social media exposure on HIV services uptake among Tanzanian Young people: Implications for enhancing the HIV response, Marineus Mutongore
  • Effective Strategies for Operating COWLHA support groups of Adolescents Living with HIV: Case of Mangochi and Chikwawa Districts of Malawi, Harry Madukani

Thursday, December 7 

  • Understanding Choice of HIV Prevention Options among Adolescent Girls and Young Women (AGYW) in Zambia, Natasha Mwila
  • Leveraging HIV to Build a Global Health Research and Development (R&D) Equity Advocacy Agenda, John Meade
  • Championing advocacy for domestic resource mobilization for health research and development in Africa, Ethel Makila

Friday, December 8 

  • Rural Youth: Underserved and Unsafe When Seeking Care, Liyema Somnono
  • Redefining Coalition Governance and Leadership in Support of Decolonizing Global Health: The Evolution of the COMPASS Coalition, Roberta Sutton
  • Collaborative Monitoring & Evaluation to Support Learning and Strengthen Advocacy Coalitions: The MERL Hub, Grace Tetteh
  • Realities faced by street children predisposing them to HIV and STIs in Dodoma and Dar es Salaam Cities in Tanzania, Simon Shilagwa 

Spotlight on New PrEP Tools and Data: From R&D to access

Tuesday, November 28

Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Staying on top of the latest advances is key for advocates, researchers, funders, and others working in HIV prevention to do their job effectively—but how can you navigate the vast amount of PrEP data online? AVAC, the Medicines Patent Pool (MPP), and Unitaid presented information on three important online PrEP resources and understand how they can support and enhance your work:

  • PrEPWatch.org: the one stop shop for PrEP resources to support introduction and scale-up, including the PrEPTracker, the only place to find information on global PrEP initiations online
  • Long Acting Therapeutics Patents and Licenses Database (LAPaL): LAPaL is the go-to resource to learn about long-acting therapeutics, their patent landscape, development and regulatory status
  • Access to Medicines Tracker: the go-to place for quarterly-updated insights on regulatory filings, regulatory approvals, and product supplies of MPP-licensed generic medicines at the country level.

Recording / Slides

Access Enablers

This graphic presents key strategies for advocates to improve vaccine access, highlighting actions like influencing WHO guidelines, community education, addressing intellectual property barriers, and establishing voluntary access mechanisms.

From the Lab to the Jab

This graphic shows all the steps to cross or overcome in the development of a new product — research & development, intellectual property barriers, registration with regulatory bodies and the implementation of products — along with the important role can advocates play.

Vaccine Manufacturing is a Multi-Stage Process Often Requires Extensive Collaboration

This graphic highlights the extensive and complex process of vaccine production, encompassing initial design, drug development, large-scale manufacturing, the creation of administration devices, and finally, distribution.

Excerpted From the Lab to Jab series.

Getting the COVID-19 Vaccines We Need

As of March 2023, the World Health Organization reported that there are 199 COVID-19 vaccines in pre-clinical development, and 183 in clinical trials. Most are injectable; but 16 candidates are intranasal, 5 are oral, 2 are inhalable, and 1 is an aerosol.

HIV Vaccine Research

HIV vaccine research is a multifaceted endeavor that requires collaboration across many disciplines to develop a vaccine that protects people from HIV infection. The graphic outlines the different areas of research that are being pursued, including vaccine platforms, immune system research, clinical research capacity, and community engagement.

Excerpted From Lab to Jab.

Introducing From the Lab to the Jab: A new series of advocates’ guides

AVAC is excited to launch From the Lab to the Jab, a new series of advocates’ guides that highlight key advocacy issues to ensure equitable access to safe, effective, and affordable vaccines.

Co-created as part of our USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR), with additional support from the New Venture Fund, From the Lab to the Jab issue briefs provide a roadmap for advocacy to advance the development and delivery of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines.

Go to avac.org/FromLabToJab to learn about next generation vaccine research and development; the basics of mRNA technology; initiatives that support local manufacturing; and understanding and overcoming barriers that undermine equitable access to vaccines. Each brief also highlights the advocacy needed to keep these efforts on track and in line with what communities need and want. 

Stay tuned for an invitation to join the From the Lab to the Jab Webinar in January 2024, and be part of the conversation that will use these briefs to strengthen advocacy and create a roadmap to achieve key transformational priorities in global health. 

Vaccine Development History

A graphic showing the duration between discovery of the microbiologic cause of selected infectious diseases and the development of a vaccine.

Excerpted From the Lab to Jab.

From the Lab to the Jab

A series of advocate guides to the latest in vaccine R&D

From the Lab to Jab are a series of briefs to learn the latest in vaccine R&D for HIV, COVID-19, TB and other global public health threats. Access them all here and stay tuned for a related webinar in early 2024. Watch this space or sign up for our email newsletter.